Hamlet PharmaHamlet PharmaHamlet Pharma
  • Home
  • About Hamlet Pharma
    • Finance and Strategy
    • Patents
    • Who Gets Cancer
  • Clinical Trials
  • Science
  • Investors
    • Financial Reports
    • Annual General Meeting 2020
  • News
  • Contact
Hamlet Pharma
Category

News

NewsPressmeddelande

Hamlet Pharma enters into Patent Licensing Agreement

News

Quest for the cure

News

Quest for the cure

NewsPressmeddelande

Successful combination of Alpha1H with chemotherapy

NewsPressmeddelande

HAMLET Pharma initiates a GLP study to evaluate if intracerebral infusion of the drug candidate Alpha1H has any toxic effects

News

Hamlet building the case for ‘bulldozer’ cancer drug

News

HAMLET Pharma releases further data from clinical study

News

HAMLET Pharma Announces Results of First Major Clinical Trial for a New Cancer Killing Molecule

News

Hamlet Pharma is proud to announce detailed timelines for the completion of the Phase I/II bladder cancer study

News

Hamlet Pharma has been granted permission for a 2-year follow up study

Previous 1 2 3 Next

HAMLET Pharma AB is a pharmaceutical company with strong links to research, working with natural and biological substances.

Swedish

© 2021 Hamlet Pharma.

  • Home
  • About Hamlet Pharma
    • Finance and Strategy
    • Patents
    • Who Gets Cancer
  • Clinical Trials
  • Science
  • Investors
    • Financial Reports
    • Annual General Meeting 2020
  • News
  • Contact

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish